

Swedish Companies Exhibiting at BIO 2004

Swedish Pavilion (Booth # 6358)

ACTIVE BIOTECH specializes in multiple sclerosis and cancer immunology therapies.

AFFIBODY AB uses protein engineering technologies to create novel protein ligands for biotherapeutic applications.

BIOTECH FORUM + SCANLAB EXHIBITION
Europe's largest Life Science Fair, Oct. 2004.

BIOVITRUM specializes in Diabetes and Obesity R&D and Biopharmaceutical processes.

CANAG DIAGNOSTICS AB develops and manufactures diagnostic tools for cancer and brain disorders.

EUROPEAN INSTITUTE OF SCIENCE AB is a venture capital and incubator firm.

GENOVIS AB provides tools for transportation of molecules in and out of living cells.

GLOBAL GENOMICS develops functional genomics tools providing unique insights into cells.

LIFE SCIENCE TECHNOLOGIES is a consulting firm specializing in Life Sciences and IT.

NEURONOVA AB develops drugs and therapeutic cells for the treatment of central nervous system disorders.

OREXO AB develops patented therapeutics based on both new and proven substances.

Medicon Valley Pavilion (Booth # 428)

ALLIGATOR BIOSCIENCE improves therapeutic and diagnostic proteins by DNA recombination.

CAMURUS provides lipid based drug delivery solutions for substances with bioavailability limitations.

CLINICAL DATA CARE manages clinical trials from study design to product approval.

LUDESI software accelerates proteomics 2D gel research.

STRICENT offers electronic data capture and knowledge management services during clinical trials.

Also Represented at BIO 2004

KAROLINSKA INSTITUTE the renowned training and research center is one of Europe's largest medical universities.

LUND UNIVERSITY is a world leader in several fields of medicine, technology and natural sciences.

At the Swedish Pavilion you may also meet **Invest in Sweden Agency, ISA** – a government agency providing professional assistance free of charge to foreign investors, and find representatives of some of our sister organizations, **Business Arena Stockholm, Position Skåne, UppsalaBIO** and the **Swedish Trade Council**.

An invitation to attend a

Breakfast Symposium on Biotechnology and Strategic Cooperation across the Atlantic

Hosted by
Invest in Sweden Agency and
Consulate General of Sweden in San Francisco

Tuesday June 8, 2004, 7.00 to 8.30 am

Bankers Club · Bank of America Building
San Francisco



Invest in Sweden Agency

www.isa.se

Stockholm
Ylva Williams
Tel: +46 8 402 78 80
ylva.williams@isa.se

New York
Erik Enroth
Tel: 212-702-8780
erik.enroth@usa.isa.se

Los Angeles
Göran Eriksson
Tel: 310-204-6790
goran.eriksson@usa.isa.se

Boston
Nigel Gaymond
Tel: 617-696-3077
nigel.gaymond@usa.isa.se



Invest in Sweden Agency

A Breakfast Symposium on Biotechnology and Strategic Cooperation across the Atlantic

Distinguished biotech executives share insights about market leaders taking strategic advantage of and benefiting from the globalization of the biotech industry. Meet executive level colleagues and Sweden's leading biotech firms.

Program - Tuesday June 8, 2004

- 7:00 am **BREAKFAST BUFFET**
- 7:30 **OPENING REMARKS** by the Hon. Barbro Osher, Consul General of Sweden
- 7:35 **PANEL DISCUSSION**
- Dr. Göran Ando, Group Chief Executive
Celltech Group plc.
- Russell Gantt, Vice President Licensing
AstraZeneca Pharmaceuticals LP
- Dr. Björn Nilsson, President & CEO
Karo Bio AB
- Moderator:**
Scott Kay, Vice President of Pharmaceutical Research
Andor Capital Management
- 8:20 – 8:30 **CONCLUDING REMARKS** by Nigel Gaymond, Special Adviser,
Invest in Sweden Agency

Start your BIO 2004 day
off on a high note!

Location

Bankers Club, top of the **Bank of America Building** at **Kearny & Pine**, in **San Francisco's financial district**.
10 minutes walk from the Moscone Convention Center.

R.S.V.P. by calling 310-204-6790
ext. 190 or via e-mail la@isa.se

Early registration is encouraged due to limited seating.

Dr. Göran Ando, Group Chief Executive
Celltech Group plc.

Dr. Ando's international career in pharma includes executive positions in management and research at Pharmacia & Upjohn in Sweden and New Jersey, US. Earlier he held executive positions at Pfizer, Bristol-Myers, Astra and Glaxo Group. In addition, Dr. Ando has served on corporate and association boards in Asia, Europe and the US.

Celltech, with HQ in UK, is a leading European biotechnology company, with a substantial long-term commitment to innovative drug discovery and development, driving its goal of becoming a global biotechnology leader.

Russell Gantt, Vice President Licensing North America
AstraZeneca Pharmaceuticals LP.

Mr. Gantt leads the licensing, partnering and divestment activities for the North America operation of AstraZeneca and is a member of the AstraZeneca Global Licensing Management Team. Gantt held similar positions at Astra Pharmaceuticals and AstraMerck, American Home Products and Schering-Plough.

AstraZeneca, with corporate HQ in UK and R&D HQ in Sweden, was formed 1999 through the merger of Astra, Sweden and Zeneca of the UK. Total R&D spending 2003 was \$3.5 billion.

Dr. Björn Nilsson, President & CEO
Karo Bio AB

Dr. Nilsson's career includes leading positions at Pharmacia & Upjohn and Amersham Pharmacia Biotech. He currently serves as chairman of the Sweden Biotechnology Industry Organization, SwedenBIO.

Karo Bio, Sweden is a leading drug discovery company for the development of precision drugs to treat major diseases targeting nuclear receptors. Currently Karo Bio enjoys strategic collaborations with Merck&Co, and Wyeth Pharmaceuticals.

Scott Kay, Vice President of Pharmaceutical Research
Andor Capital Management

Mr. Kay was previously Senior US Pharmaceutical Analyst at Banc of America Securities and has held various management positions in sales and marketing at Pfizer.

Andor Capital Management is one of the largest hedge fund advisors in the world with approximately \$7 billion in assets under management.

Nigel Gaymond, Special Adviser
Invest in Sweden Agency

A native of Bristol, England, Mr. Gaymond has consulted on both sides of the Atlantic over nearly two decades specializing in Life Sciences. He also operates BELS, a network of expatriate "Brits" working in the life sciences.

Invest in Sweden Agency - Life Sciences

A force in biotech

A flexible research environment explains the biotech industry's strong position in Sweden. With more than 200 biotech companies, Sweden hosts Europe's fourth-largest biotech community and the largest measured per capita.

The unique Swedish system of "professor's exemption," where academic researchers retain patent rights to their own discoveries, is one of the cornerstones of the biotech industry. The free movement of researchers between academia and corporations leads to a stream of new biotech start-ups. This constant interplay gives Swedish biotech firms access to the latest scientific research. According to a survey by the Swedish Agency for Innovation (Vinnova), as many as 93 percent of all Swedish biotech companies are involved in R&D collaborations with academic researchers.

Three of Europe's strongest clusters of biotechnology are found in Sweden: Stockholm/Uppsala, Göteborg and Malmö/Lund, according to the Boston Consulting Group.

Companies planning to establish or expand business operations in Sweden can, free of charge, obtain information and assistance from ISA and its regional and international network.



Invest in Sweden Agency

www.isa.se